0.91%| Prev Close: | 21.63 |
|---|---|
| Open: | N/A |
| Bid: | 21.05 x 1300 |
| Ask: | 28.78 x 100 |
| 1y Target Est: | 24.60 |
| Beta: | 0.540 |
| Next Earnings Date: | N/A |
| Day's Range: | N/A - N/A |
|---|---|
| 52wk Range: | 10.60 - 21.80 |
| Volume: | 0 |
| Avg Vol (3m): | 184,769 |
| Market Cap: | 553.81M |
| P/E (ttm): | N/A |
| EPS (ttm): | -1.22 |
| Div & Yield: | N/A (N/A) |
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Three Therapeutic Approaches That Are Worthy of Your Due Diligenceat Motley Fool(Mon, Jun 17)
- Why Did Immunotherapy Pioneer NewLink Genetics Reach A 52-Week High?at Seeking Alpha(Mon, Jun 10)
- NEWLINK GENETICS CORP Files SEC form 8-K, Entry into a Material Definitive AgreementEDGAR Online(Wed, Jun 5)
- Two Diversified Biotechs to Watch After Impressive ASCO Dataat Motley Fool(Mon, Jun 3)
- NewLink Genetics' Algenpantucel-L Shows Encouraging Disease-Free and Overall Survival in Phase 2 Study in Resected Pancreatic CancerPR Newswire(Mon, Jun 3)
- NewLink Genetics Presents Results from Two Phase 1 Studies with Immunotherapy Agent, Indoximod, at the ASCO 2013 Annual MeetingPR Newswire(Mon, Jun 3)
- NEWLINK GENETICS CORP Files SEC form 8-K, Other EventsEDGAR Online(Mon, Jun 3)
- NewLink Genetics Presents Positive Phase 2 Data on Novel Immunotherapy, Tergenpumatucel-L, in Non-Small Cell Lung Cancer at the ASCO 2013 Annual MeetingPR Newswire(Sat, Jun 1)
- NewLink Genetics to Present at the Jefferies 2013 Healthcare ConferencePR Newswire(Wed, May 29)
- NewLink Genetics to Be Added to NASDAQ Biotechnology IndexMarketwired(Thu, May 16)
- NewLink Genetics to Present Data on Cancer Immunotherapy Programs at the ASCO 2013 Annual MeetingMarketwired(Thu, May 16)
- NEWLINK GENETICS CORP Files SEC form 8-K, Other EventsEDGAR Online(Thu, May 16)
- NEWLINK GENETICS CORP FinancialsEDGAR Online Financials(Wed, May 15)
- NEWLINK GENETICS CORP Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles of Inc. oEDGAR Online(Tue, May 14)
- 3 Biotech Stocks Spiking With Big Volumeat TheStreet(Mon, May 13)
Press Releases
- NewLink Genetics' Algenpantucel-L Shows Encouraging Disease-Free and Overall Survival in Phase 2 Study in Resected Pancreatic CancerPR Newswire(Mon, Jun 3)
- NewLink Genetics Presents Results from Two Phase 1 Studies with Immunotherapy Agent, Indoximod, at the ASCO 2013 Annual MeetingPR Newswire(Mon, Jun 3)
- NewLink Genetics Presents Positive Phase 2 Data on Novel Immunotherapy, Tergenpumatucel-L, in Non-Small Cell Lung Cancer at the ASCO 2013 Annual MeetingPR Newswire(Sat, Jun 1)
Reports
- ValuEngine Industry Report for Medical-biomed/geneticsValuEngine, Inc.(Jun 19)
- NEWLINK GENETICS CP (NLNK) 12-months forecastPechala's Reports(Jun 15)
- Wright Industry Averages: Pharmaceuticals & Biotechnology (Global)Wright Reports(Jun 14)